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(57) ABSTRACT 
The present invention provides systems for growing two or 
three dimensional mammalian cells within a culture medium 
facilitated by an electromagnetic field, and preferably, a time 
varying electromagnetic field. The cells and culture medium 
are contained within a fixed or rotating culture vessel, and 
the electromagnetic field is emitted from at least one elec- 
trode. In one embodiment, the electrode is spaced from the 
vessel. The invention further provides methods to promote 
neural tissue regeneration by means of culturing the neural 
cells in the claimed system. In one embodiment, neuronal 
cells are grown within longitudinally extending tissue 
strands extending axially along and within electrodes com- 
prising electrically conductive channels or guides through 
which a time varying electrical current is conducted, the 
conductive channels being positioned within a culture 
medium. 
2,996,429 A * 811961 Toulmin, Jr. ................ 4351391 25 Claims, 11 Drawing Sheets 
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In the preferred embodiment, the presence of the time may be introduced as necessary to achieve adequate mass 
varying electromagnetic field potentiates the growth of transfer for each embodiment. 
nerve and other tissue. The time varying field may be In one embodiment, illustrated in FIGS. 10 and 11, 
induced by either: 1) a time varying current within a slip-ring contacts or their equivalents are electrically con- 
conductor, or 2) a time varying voltage between fixed s nected to the ends of the channels, and an external power 
conductors. In one embodiment, for example, the culture is source is provided for applying the time varying electrical 
placed nearby a conductor through which a time varying current defining the waveform through the channels. In 
current is passed, or between parallel plates upon which a another embodiment, the channel consists of a pair of 
time varying voltage is applied. In both cases, a time varying parallel, mutually spaced conductors across which a time 
electromagnetic field results within the area of interest, i.e., varying voltage is applied. This also achieves the time 
in the region of the cell culture. varying electromagnetic field but restricts it to the region 
The system and process are utilized in combination with between the parallel electrodes, which is advantageous for 
known tissue culture processes to produce enhanced cell directing localized growth according to a desired physical 
growth, directed cell growth, and tissue formation and pattern. The present invention also relates to a system and 
organization. 15 method for culturing primarily two dimensional mammalian 
A will be understood from the description to follow, the cells facilitated by a time varying electromagnetic field. The 
system is operable to up or down the activity of electrodes may either be in direct galvanic contact or gal- 
specific genes, general, growth promoting genes are up vanically isolated from the target cells. The present inven- 
regulated and growth inhibitory genes are down regulated. tion Provides a strategy to re-engineer nerve tissue and 
The effect is shown to persist for some period after termi- 2o myoneural junctions and can be used medically for axonal 
nation of the applied time varying field. This persistent, regeneration. 
growth promoting effect subsides after a period of some In one embodiment of the present invention, there is 
days, and the cells return to a growth state characterized by provided a system for growing three dimensional mamma- 
controls, having never been exposed to the fields. This is lian cells, comprising a rotating wall vessel containing a 
tions for clinical medical care, i.e. nerve regeneration, are varying electromagnetic field is applied to enhance tissue 
therefore safer than if the “pseudo transformed” state per- growth which may occur on a shaped substrate. The elec- 
sisted. The set of gene transformations, associated with the tromagnetic field may be generated by means such as by 
time varying electromagnetic field, also promote the ability directing the current waveform directly through a conduc- 
of the growing tissue to adhere and thrive on substrates by 30 tive substrate (or substrate layer) or by projecting the field 
the induction of genes leading to the secretion of extracel- from an external antenna, or electrode adjacent to and 
lular materials favorable to the tissue microenvironment. spaced from the medium, the spacing being sufficiently 
of producing the tirne varying electro- small relative to the strength of the electromagnetic field to 
magnetic field in the vicinity of the living tissue culture are induce effectual levels of electromagnetic field within the 
encompassed. In one embodiment, an array of conductive 35 medium, in aCCOrdance with the Particular application. A 
current carrying elements (or voltaic electrodes) are time varying electromagnetic field may be emitted from a 
arranged so as to intensify or focus the time varying elec- nearby plate or other suitable “antennae,” or a time varying 
tromagnetic (EM) field onto the culture. Each embodiment voltage may be applied across suitable electrodes (such as 
is characterized by a method for application of the time Plates) to Produce the time varying electromagnetic field. 
varying field to the target tissue, such as neuronal, for 40 The field generation system may either be rotating with the 
stimulation of growth, or repair or induction of changes in vessel Or fixed, and spaced from, the rotating vessel. The 
gene activity patterns, The term “field generator” is used rotating wall vessel can be a rotating wall perfused vessel or 
herein to represent these various embodiments for generat- a rotating wall batch-fed vessel. 
ing the time varying electromagnetic fields. In its simplest The time varying electromagnetic field is advantageously 
form, it is a conductive electrode, placed near the target 45 produced by a varying electrical potential in the form of a 
cells, through which current is directed from a controlled square wave having a frequency of approximateb ten cycles 
waveform current source. per second. In one embodiment, a current of about ten 
A suggested above, in one embodiment, the field gen- milliamps, conducted between opposite corners of a metallic 
erator is in the form of a conductive channel mounted on or conductor, Produces a stimulatory time varying electromag- 
embedded in a disc of biocompatab~e material, (FIG, 11) so netic field extending several centimeters from the plate 
one or within a surface. In practice, the range of frequency and oscillating 
rotational bioreactor so as to obtain the beneficial culture electromagnetic field strength is a Parameter which may be 
conditions associated therewith, The of the selected to for achieving the desired stimulation of particular 
stimulatory electromagnetic field with the rotational tissues, cells, Or genes, and for Providing the appropriate 
environment, known to permit morphological expression ss m ~ ~ n t  of uP/down reda t ion  of these genes. 
beyond conventional culture, is particularly effective. This is In one embodiment of the present invention, the cell 
because the induced pattern of growth enhancing genes is growth substrates or carriers are spherical disks containing 
permitted to be ultimately expressed, as cell growth and multiple parallel channels (FIG. 10) which are coated with 
tissue formation, without mechanical inhibition from the a bioattractive material. The bioattractive material has a 
culture apparatus. Also the inherent growth advantages well 60 longitudinal axis across which the time varying electrical 
known in the rotational systems is synergistic with the potential is applied and through which a time varying 
beneficial in certain applications, in that medical applica- 25 cell-rich medium and a formed cell growth substrate. A time 
several 
of these discs may be then 
growth stimulation derived from the time varying electro- 
magnetic field. The conditions may be further optimized by 
utilizing actual microgravity, in space. In this application, 
mechanical rotation of the cell culture vessel is not required 65 conium and platinum. 
but may be utilized to achieve mixing and sufficient mass 
transfer to sustain a healthy culture. Other forms of mixing 
current is conducted. The mammalian cells adhere to the 
bioattractive material and are free to orient, as they grow. 
Representative bioattractive materials include titanium, zir- 
The class of mammalian cells preferably is selected from 
the group consisting of neuronal cells, normal human neu- 
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ronal progenitor cells (NHNP), and a cell responding to the 
time varying electromagnetic field. It will be understood by 
those of ordinary skill in the art that the teachings of the 
present invention apply to other cell types. 
In another embodiment of the present invention, there is 
provided a method of culturing mammalian cells in the 
claimed system, comprising the steps of inoculating the cells 
into the vessel containing a culture medium, rotating the 
vessel to enhance the proliferation of the cells and, in one 
embodiment, to initiate the attachment of the cells to micro- 
carrier spheres or beads suspended within the culture 
medium, applying a time varying electromagnetic field to 
the culture medium, cells, and cell carriers, and measuring 
the growth of the cells. Preferably, the vessel is rotated at a 
speed from about 2 RPM to 30 RPM, and the time varying 
electromagnetic field is generated by a time varying current 
passed through a conductor with RMS value of about 1 to 
1,000 ma. In one embodiment, a range of about 1 mA to 6 
mA is used. 
In still another embodiment of the present invention, there 
is provided a system for growing two-dimensional neural 
cells, comprising a petri dish containing a cell culture 
medium and an electrode placed in the center of the petri 
dish. In this embodiment, the electrode serves as the field 
generator. Preferably, the neural cells are applied directly on 
the electrode. As a result, the neutral cells exhibit acceler- 
ated growth. 
In yet another embodiment of the present invention, there 
is provided a system for growing two-dimensional neural 
cells further comprising a slide placed on the electrode. 
Preferably, the neural cells are applied, e.g., bubbled, on the 
slide instead of directly contacting the electrode, and 
preferably, the current producing the waveform is applied at 
a strength range of from about 1 mA to about 100 mA, and, 
in one embodiment, suitably from about 1 mA to 6 mA. 
In still another embodiment of the present invention, there 
is provided a method of treating an individual having 
diseased neuronal cells, comprising the steps of growing 
neuronal cells in the claimed two- or three- dimensional 
systems and transplanting the neuronal cells into the indi- 
vidual. Such diseases include Parkinson’s disease, diseases 
of neuromuscular junction and Alzheimer’s Disease. Neural 
trauma can also be treated in same methodology. 
In yet another embodiment of the present invention, the 
time varying electromagnetic field (or electrical potential) 
induces cellular response including cellular control of 
growth and differentiation at gene level. Preferably, the 
cellular control of growth and differentiation is to suppress 
or enhance growth regulatory functions at gene level. Still 
preferably, the gene is associated with increased tissue and 
cell proliferation. 
Other and further aspects, features, and advantages of the 
present invention will be apparent from the following 
description of the presently preferred embodiments of the 
invention given for the purpose of disclosure. 
BRIEF DESCRIPTION OF THE DRAWINGS 
So that the matter in which the above-recited features, 
advantages and objects of the invention, as well as others 
which will become clear, are attained and can be understood 
in detail, more particular descriptions of the invention 
briefly summarized above may be had by reference to 
certain embodiments thereof which are illustrated in the 
appended drawings. These drawings form a part of the 
specification. It is to be noted, however, that the appended 
drawings illustrate preferred embodiments of the invention 
and therefore are not to be considered limiting in their scope. 
6 
FIG. 1 shows a petri dish with cells in a concentrated 
bubble placed on the metal electrode in the center of the 
dish. 
FIG. 2 shows normal human neuronal progenitor (NHNP) 
5 cells grown in conventional tissue culture procedures. 
FIG. 3 shows the perimeter of non-waveform influenced 
normal human neuronal progenitor cells 24 hours after the 
experiment. 
FIG. 4 shows neural tube formation within normal human 
neuronal progenitor cells under the influence of waveform. 
FIG. 5 shows neural tube generation within normal 
human neuronal progenitor cells under the influence of 
waveform. 
FIG. 6 shows the composition of waveform-influenced 
neural tissue 24 hours after the exposure. 
FIG. 7 shows the waveform-influenced normal human 
neuronal progenitor cells 24 hours after the exposure. 
FIG. 8 shows a close-up of waveform-influenced normal 
FIG. 9 shows waveform-influenced normal human neu- 
ronal progenitor cells 24 hours after the exposure. 
FIG. 10  shows prototype of the system 1,  consisting of 
silicon plates 2, fluid coupling 3, slip rings 4, a rotating wall 
pressure vessel (RWPV) 5,  electrical conductor 6 (i.e., an 
electrical conductive bioattractive inlay strip), a perfusion 
inlet 7, perfusion outlet 8, a stand for the rotating wall 
pressure vessel 9 and a source of time varying electrical 
FIG. 11A is a plan view of one of the disc-shaped silicon 
plates 2, showing a central opening 11 about which rotation 
occurs, the electrical conductors 6, and electrical contacts 12 
connected to the strips at opposite ends thereof. 
FIG. 11B is a side view of the silicon plate 2, demon- 
strating the electrical contacts 12 and the electrical conduc- 
tive strips, in the form of bioattractive inlays 6. 
DETAILED DESCRIPTION OF THE 
INVENTION 
1 u  
is 
2o human neuronal progenitor cells. 
2s 
3o current 10. 
35 
40 
As used herein, the term “bioattractive material” shall 
refer to materials to which a cellular material will attach. 
As used herein, the term “longitudinally orient” shall refer 
to orientation in an elongated cordlike fashion. 
As used herein, the term “parallel channels” shall refer to 
electric channels which are designed to provide constant 
output to all the electrodes simultaneously. 
As used herein, the term “cell carriers” shall refer to 
microcarrier beads, scaffolds and matrices which support the 
As used herein, the term “rotating wall batch-fed vessel” 
shall refer to slow turning lateral vessel (STLV) and high 
aspect rotating vessel (HARV). 
As used herein, the term “Corona Effect” shall refer to the 
accelerated growth pattern of neuronal cells electrically 
potentiated by waveform. 
In one preferred embodiment, the present invention is 
directed to the growth of three dimensional mammalian 
60 neuronal tissue using an electrically conductive strip in the 
form of a channel or mold coated with a bioattractive or 
biocompatable material to which an electrical potential is 
applied to longitudinally orient the neural cells or axons as 
they adhere to the bioattractive material which is suspended 
65 in an axon rich medium. 
Specifically, in the present embodiment, the apparatus 
includes a bioreactor chamber vessel employing electrically 
4s 
so growth and/or attachment of cellular materials. 
ss 
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insulative, biocompatable spherical disks of a material such diseased neuronal cells, comprising the steps of growing 
as silicon. These disks rotate inside the pressure vessel. Each neuronal cells in the two or three dimensional systems 
disk has multiple parallel channels cut into its surface. The disclosed herein and transplanting the grown neuronal cells 
channels have a semicircular cross-section and contain an into the individual. Such diseases include Parkinson’s 
electrically conductive inlay in the form of a channel-shaped s disease, diseases of neuromuscular junction and Alzheimer’s 
conductive strip of a bioattractive material such as Disease. Neural trauma can also be treated with this same 
zirconium, titanium and platinum. Each channel strip 6 has methodology. 
an electrical contact on each longitudinal end that is used to yet another embodiment of the present invention, the 
create and control an electrical potential along the length of waveform (or electrical potential) induces a cellular 
the strip. The vessel is filled with a medium and the disks are i o  response including cellular control of growth and differen- 
rotated within a medium containing axons. The cells adhere tiation at gene level, preferably, the cellular control of 
to the electrically conductive bioattractive inlay material. growth and differentiation is to suppress or enhance growth 
The desired longitudinal cell orientation and therefore the regulatory functions at gene level, Still preferably, the gene 
structure of the resulting tissue is affected and/or controlled is associated with embryogenesis, 
The following examples are given for the purpose of by the electrical stimulus. 
The present invention is also directed to the growth of two illustrating various embodiments of the invention and are 
dimensional mammalian neuronal tissue using electrodes. not meant to limit the present invention in any fashion, 
The electrodes are either in direct contact or not in contact 
with the target cells. 
provided a system for growing three dimensional mamma- 
lian cells, comprising a rotating wall vessel containing a 
cell-rich medium, cell carriers placed within the vessel and 
an electrical potential applied to the cell carrier. Preferably, 
the rotating wall vessel can be a rotating wall perfused vessel 25 culture following standard cell culturing procedures, 
or a rotating wall batch-fed vessel. 
In one embodiment of the present invention, the cell 
carriers are spherical disks containing multiple parallel 
channels, which are coated with a bioattractive material. 
More preferably, the bioattractive material has a longitudinal 
axis across which the electrical potential is applied. The 
mammalian cells adhere to the bioattractive material and are 
therefore oriented longitudinally upon the electrical stimu- 
lus. Representative bioattractive materials include titanium, 35 coated or not coated), ~ l ~ ~ ~ ~ ~ d ~ ~  were made of 
zirconium and platinum. 
In the methods of the present invention, the mammalian 
cell is selected from the group consisting of a neuronal cell, 
a normal human neuronal progenitor cell (NHNP) and a cell 
responding to waveform. A person having ordinary skill in 4o 
this art will be able to apply the teachings of the present 
invention to other cell types. 
In another embodiment of the present invention, there is 
Provided a method of culturing mmmdian  cells in the Initially, a metal electrode was placed inside a petri dish 
claimed system, comprising the steps of inoculating the cells 45 and centered. Normal human neuronal progenitor cells were 
into the vessel, rotating the vessel to initiate the attachment seeded at 2x105 cells in 0.7 ml of media and carefully 
of the cell to the cell carriers, applying an electrical Potential dropped on the electrode in a concentrated bubble (FIG. 1). 
to the cell carriers and measuring the growth of the cells. Cells were incubated for 2 days. Second day after seeding is 
Preferably, the vessel is rotated at a speed from about 10 considered day 0 of the experiment. At day 0, each dish was 
RPM to 30 RPM, and the electrical Potential is applied at a 50 given 15 ml of media and waveform was applied to seven 
strength range of from about 1 mA to about 6 mA. electrodes. Cells were observed under a dissecting micro- 
In still another embodiment of the present invention, there scope and fed with 15 ml of media at day 3, and 13 ml every 
is provided a system for growing two-dimensional neural three days at day 6, 9 and 12. At day 14, the cells were fed 
cells, comprising a petri dish containing a cell culture again with 13 ml of media. At day 17, the cells were 
medium and an electrode placed in the center of the petri 55 incubated for 10 minutes in a Collagenase/DNase cocktail, 
dish. The electrode is charged with a waveform. Preferably, then trypsin was directly applied to the cocktail and the cells 
the neural cells are bubbled directly on the electrode. As a were further incubated for 3 more minutes. Before the media 
result, the neutral cells exhibit accelerated growth. was added to deactivate trypsin, the cocktail mix was 
In yet another embodiment of the present invention, there pipetted up and down several times. The cells were washed 
is provided a system for growing two-dimensional neural 60 twice with IxPBS, reapplied with the media and placed on 
cells further comprising a slide placed on the electrode. ice. The cells were counted, assessed for viability. 
Preferably, the neural cells are bubbled on the slide instead To examine the accelerated growth of cells 48 and 72 
of directly contacting the electrode. Preferably, the wave- hours after waveform was discontinued, cells were treated 
form is applied at a strength range of from about 1 mA to the same as above, except that after day 14 treatment, instead 
about 6 mA. 65 of harvesting, two dishes from the non-waveform group 
In still yet another embodiment of the present invention, (control) and two dishes from the waveform group were 
there is provided a method of treating an individual having randomly chosen and re-seeded at 9x10’ cells in two new 
EXAMPLE 1 
Cells 
In one embodiment of the present invention, there is 2o 
~~~~~l human neuronal progenitor cells (NHNP) were 
pooled from three donors, controls, normal human neu- 
ronal progenitor cells were grown in conventional tissue 
EXAMPLE 2 
Materials 
30 
GTSF-2 medium with 10% FBS, ~ i ~ ~ ~ f l ~ ~ ~ ~ i ~  and F ~ ~ -  
gizone was used to culture the cells, l x p ~ s ,  collagenase, 
D N ~ ~ ~  and ~ ~~~i~ were purchased from clonetics, The 
cells were grown on 12-100 mm Petri dishes (tissue culture 
and 
stainless steel. A waveform generator was used to generate 
the waveform in a strength of 1-6 mA(AC) square wave, 10 
Hz variable duty cycle, 
EXAMPLE 3 
Electrically Potentiating Cell Growth When 
Electrode is in Direct Contact with the Target Cells 
US 6,673,597 B2 
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petri dishes each, with a total of four dishes. Cells from one 
set (#11 waveform and control #6) were counted and pho- 
tographed 48 hours after seeding, and cells from the second 
set (#12 waveform and control #7) were counted and pho- 
tographed 72 hours after seeding. 
To examine accelerated growth pattern “Corona Effect” 
after the electrical potentiation, the same treatment was 
applied to the cells without harvesting. A dish each from 
waveform group and non-waveform group were chosen 
randomly. Cells still attached in sheet from were lifted off of 
the electrodes carefully and placed in new petri dishes with 
medium, and then photographed 24 hours later. 
EXAMPLE 4 
Electrically Potentiating Cell Growth When 
Electrode is not in Direct Contact with the Target 
Cells 
Initially, a metal electrode was placed inside a petri dish 
and centered. A slide was carefully placed on the electrode 
under sterile conditions. Normal human neuronal progenitor 
cells were seeded at 2x10’ cells in 0.7 ml of media and 
bubbled on the slide. Cells were incubated for 2 days. 25 ml 
of media were applied and two 1000 pl pipetman blue tips 
were placed in the dish to anchor the slide to bottom of the 
dish. The second day after seeding was considered day 0 of 
the experiment. At day 0, each dish was given 25 ml of 
media and waveform was applied to six of the twelve 
electrodes. 
Cells were observed under a dissecting microscope and 
fed with 25 ml of media every three days at day 3, 6, 9 and 
12. At day 14, the cells were fed again with 25 ml of media. 
At day 18, the cells were incubated for 10 minutes in a 
CollagenaseiDNase cocktail, then typsin was directly 
applied to the cocktail and the cells were further incubated 
for 3 more minutes. Before the media was added to deac- 
tivate trypsin, the cocktail mix was pipetted up and down 
several times. The cells were washed twice with IxPBS, 
reapplied with the media and placed on ice. The cells were 
counted, assessed for viability and then replated at 100,000 
per plate. The remaining waveform and non waveform slides 
were fixed and refrigerated for staining at a later date. 
EXAMPLE 5 
Electrically Potentiated Growth of Cells 
Normal human neuronal progenitor-pool cells exposed to 
a time varying electromagnetic field (waveform), either in 
direct contact or not in direct contact with the electrode, 
displayed an accelerated growth rate and different morphol- 
ogy as compared to non waveform cells (control), i.e., cells 
not subject to the time varying electromagnetic field (see 
Table 1 and Table 2, FIGS. 2-9). After the application of the 
time varying electromagnetic field or waveform, the cells 
preferentially aligned, while cells without waveform expo- 
sure showed random pattern. Cells in direct contact with the 
electrode remained stimulated up to at least 72 hours after 
waveform was removed (Table 3); while those not in direct 
contact with the electrode once removed from waveform 
continued to experience accelerated and long term stimula- 
tion growth pattern even after 168 hours (Table 4). Viability 
was also higher in the cells exposed to the waveform (Table 
4). Cells were suspended easily with the CollagenaseiDNase 
then trypsin sequence. 
10 
TABLE 1 
*Cell Count and Viability at Harvest (day 17) 
5 
NHNP-POOL CELL COUNT VIABILITY HARVEST 
Waveform 1 860,000 98% 17 days 
Waveform 2 1,000,000 98% 17 days 
Waveform 3 1,000,000 98% 17 days 
10 Waveform 4 1,300,000 98% 17 days 
Waveform 7 1,000,000 98% 17 days 
Waveform 8 940,000 98% 17 days 
Waveform 9 700,000 98% 17 days 
Waveform 10 1,000,000 98% 17 days 
1s Control 1 500,000 98% 17 days 
Control 2 400,000 98% 17 days 
Control 3 300000 98% 17 days 
Control 4 500,000 98% 17 days 
Control 5 400,000 98% 17 days 
*Cells were in direct contact with the electrode. 
20 
TABLE 2 
2s  *Cell Count and Viabilitv at Harvest (dav 18) 
NHNP-POOL CELL COUNT VIABILITY HARVEST 
Waveform 1 1,000,000 100% 18 days 
Waveform 5 1,100,000 100% 18 days 
3o Control 1 800,000 100% 18 days 
Control 5 800,000 100% 18 days 
*Cells were not in direct contact with the electrode. 
3 s  TABLE 3 
*Cell Count at Various Times after Removal of Waveform 
CELLS COUNT HOURS OFF ELECTRODE 
Waveform 11 
40 Control 6 
Waveform 11 
Control 6 
Waveform 12 
Control 7 
Waveform 12 
45 Control 7 
520,000 
112,000 
274,000 
48,000 
576,000 
96,000 
228,000 
120,000 
Counted and re-seeded at 96,000iplate 
Counted and re-seeded at 96,000iplate 
48 hours off electrode 
48 hours off electrode 
Counted and re-seeded at 96,000iplate 
Counted and re-seeded at 96,000iplate 
72 hours off electrode 
72 hours off electrode 
*Cells were in direct contact with the electrode. 
TABLE 4 
so 
*Cell Count and Viabilitv at Various Times after Harvest 
TIME AFTER 
HARVEST 
NHNP-POOL CELL COUNT VIABILITY (Hours) 
Waveform 1 56,000 85% 24 
Waveform 5 40,000 85% 24 
Control 1 36,000 65% 24 
Control 5 28,000 65% 24 
Waveform 1 188,000 98% 48 
6o Waveform 5 212,000 98% 48 
Control 1 74,000 87% 48 
Control 5 162,000 90% 48 
55 
Waveform 1 3,400,000 100% 120 
Waveform 5 3,400,000 100% 120 
Control 1 900,000 99% 120 
Control 5 900,000 99% 120 
65 Waveform 1 4,000,000 100% 168 
Waveform 5 3,800,000 100% 168 
US 6,673,597 B2 
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TABLE 4-continued 
12 
TABLE 5-continued 
*Cell Count and Viabilitv at Various Times after Harvest Down Regulated Genes in Descending Order (Highest to lowest) 
Homo sapiens mRNA expressed in osteoblast, complete cds TIME AFTER 22. 
HARVEST {Incyte PD:2537863} 
24. 
NHNP-POOL CELL COUNT VIABILITY (Hours) 23. EST {Incyte PD:3204745} 
Control 1 980,000 97% 168 {Incyte PD:2732630} 
Control 5 900,000 95% 168 25. Homo sapiens serum-inducible kinase mRNA, complete cds 
10 {Incyte PD:1255087} 
*Cells were not in direct contact with the electrode. 
Homo sapiens mRNA for serineithreonine protein kinase SAK 
26. 
27. EST {Incyte PD:660376} 
28. GRANCALCIN {Incyte PD:1671852} 
29. N-CHIMAERIN {Incyte PD:1852659} 
30. 
31. Adenylosuccinate lyase {Incyte PD:1653326} 
32. EST {Incyte PD:1798393} 
33. 
Carbonic anhydrase I1 {Incyte PD:2474163} 
Homo sapiens Pig10 (PIG10) mRNA, complete cds {Incyte EXAMPLE 6 
15 PD:1731061} 
Waveform Gene Array Display (GAD) Results 
Homo sapiens HP protein (HP) mRNA, complete cds {Incyte 
PD:3084122) Normal Human Neural Progenitor cells or human adult 
astrocytes were exposed to waveform and non-waveform 
growth conditions for 17 days. Upon completion of the 
exposure period cells were harvested via trypsinization and 
poly-RNA was prepared from the respective groups of cells. 
RNA samples were quick frozen and shipped to Synteni 
Corporation for GAD analysis. Below are the results of a 
survey of the response of over 10,000 human genes. The 
results were divided into two categories (Table 5 and Table 
6). Those genes down regulated or suppressed by the wave- 
form and those up regulated or enhanced in activity by the 
waveform. 
An analysis of the data indicates a significant down 
regulation of maturation and regulatory genes. These matu- 
ration and regulatory genes are normally associated with the 
differentiated or non-growth profile of normal cells. 
However, there is a significant up regulation of some 150 
genes which are mainly associated with growth and cellular 
proliferation. Neither two nor three dimensional growth of 
neural cells has been achieved prior to this event with the 
positive outcome of enhanced growth and apparent gene 
regulatory control. 
TABLE 5 
Down Regulated Genes in Descending Order (Highest to lowest) 
34. 
2o 3s. 
36. 
37. 
38. 
25 39. 
40. 
41. 
42. 
43. 
44. 
4s. 
46. 
47. 
48. 
49. 
so. 
40 2;: 
53. 
54. 
30 
3 s  
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
Homo sapiens (clone Zap2) mRNA fragment {Incyte PD:1661837] 
CDC28 protein kinase 2 {Incyte PD:1384823} 
Synteni: YCFR 22 {YC 22.2OOO.W} 
ESTs, Moderately similar to cell growth regulating nucleolar 
protein LYAR [M.mwcuZus]{Incyte PD:2233551} 
KERHIN, TYPE I1 CYTOSKELETAL 7 {Incyte PD:1649959} 
MITOTIC KINESIN-LIKE PROTEIN-1 {Incyte PD:2640427} 
EST {Incyte PD:674714} 
Synteni: YCFR 22 {YC 22.2OOO.X} 
Synteni: YCFR 26 {YC 26.0062.N) 
Synteni: YCFR 22 {YC 22.2OOO.Z} 
Transcription factor 6-like 1 (mitochondrial transcription factor 
1-like) {Incyte PD:3371995} 
Interferon-inducible 56-KDa protein {Incyte PD:1215596} 
EST {Incyte PD:1794375} 
Homo sapiens mitotic feedback control protein Madp2 homolog 
mRNA, complete cds {Incyte PD:2414624} 
EST {Incyte PD:151026} 
Homo sapiens Pig3 (PIG3) mRNA, complete cds {Incyte PD: 
2395269) 
General transcription factor IIIA {Incyte PD:1527070} 
Cellular retinoic acid-binding protein [human, skin, 
mRNA, 735 nt] {Incyte PD:585432} 
EST {Incyte PD:1755159} 
Homo sapiens mRNA for KIAAO285 gene, complete cds {Incyte 
PD:1738053} 
ESTs, Weakly similar to F25HS.h [C.eZegans] {Incyte PD: 
1923567) 
45 56. 
57. 
58. 
59. 
SO 60. 
61. 
62. 
63. 
64. 
65. 
66. 
60 67. 
68. 
55 
69. 
65 70. 
ESTs, Modeiately similar to TlOC6.i [C.eZegans] 
{Incyte PD:1923186} 
Chromosome condensation 1 {Incyte PD:3180854} 
Calmodulin 1 (phosphorylase kinase, delta) {Incyte PD: 
2803306) 
Centromere protein A (17kD) {Incyte PD:2444942} 
V-jun avian sarcoma virus 17  oncogene homolog {Incyte PD: 
1920177) 
Human glutathione-S-transferase homolog mRNA, complete cds 
{Incyte PD:1862232} 
Homo sapiens gene for protein involved in sexual development, 
complete cds {Incyte PD:3033934} 
EST {Incyte PD:2630992} 
Human low-Mr GTP-binding protein (RAB32) mRNA, partial cds 
{Incyte PD:1662688} 
Annexin 111 (lipocortin 111) {Incyte PD:1920650} 
Hydroxymethylbilane synthase {Incyte PD:1509204} 
Synteni: HK 4 {HK 4.2000.Y) 
Ribosomal protein L7a {Incyte PD:2579602} 
Human mRNA for myosin regulatory light chain {Incyte PD: 
78783) 
Ferredoxin reductase {Incyte PD:1819763} 
Human copper transport protein HAHl (HAH1) mRNA, 
complete cds {Incyte PD:2313349} 
Human G protein gamma-11 subunit mRNA, complete cds 
{Incyte PD:1988432} 
Synteni: HK 4 {HK 4.2000.W} 
Human XIST, coding sequence a mRNA (locus DXS399E) {Incyte 
PD:1514318) 
Ribosomal protein, large, PO {Incyte PD:3511355} 
Homo sapiens clone 23714 mRNA sequence {Incyte PD:1728368} 
Human mRNA for ApolLHuman (MERS(Aop1-Mouse)-like 
protein), complete cds {Incyte PD:2527879} 
Synteni: HK 4 {HK 4.2000.Z} 
Proteasome (prosome, macropain) subunit, beta type, 5 {Incyte 
PD:2503119} 
Human PINCH protein mRNA, complete cds {Incyte PD:126888} 
Homo sapiens peroxisome assembly protein PEXlO mRNA, 
complete cds {Incyte PD:998279} 
Homo sapiens short chain L-3-hydroxyacyl-CoA dehydrogenase 
(SCHAD) mRNA, complete cds {Incyte PD:1638850} 
Neuroblastoma RAS viral (v-ras) oncogene homolog {Incyte 
PD:2816984} 
H.sapiens mRNA for b4 integrin interactor {Incyte PD:1932850} 
Human forkhead protein FREAC-1 mRNA, complete cds {Incyte 
PD:1449920} 
Human mRNA for protein D123, complete cds {Incyte 
PD: 1920522) 
H.sapiens mRNA for A-kinase anchoring protein AKAP95 {Incyte 
PD:1628787} 
Carbonyl reductase {Incyte PD:1633249} 
EST {Incyte PD:2060973} 
ESTs, Highly similar to GUANINE NUCLEOTIDE-BINDING 
PROTEIN G(I)/G(S)/G(O) GAMMA-7 SUBUNIT 
[Rattus nowegicw] {Incyte PD:1640161} 
Homo sapiens Na+/Ca+ exchanger mRNA sequence {Incyte 
PD:2880435} 
STRESS-ACTIVHED PROTEIN KINASE JNKl {Incyte 
PD:3331719} 
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TABLE 5-continued 
Down Regulated Genes in Descending Order (Highest to lowest) Down Regulated Genes in Descending Order (Highest to lowest) 
71. 
72. 
73. 
74. 
7s. 
76. 
77. 
78. 
79. 
80. 
81. 
82. 
83. 
84. 
85. 
86. 
87. 
88. 
89. 
90. 
91. 
92. 
93. 
94. 
9s. 
96. 
97. 
98. 
99. 
100. 
101. 
102. 
103. 
104. 
105. 
106. 
107. 
108. 
109. 
110. 
111. 
112. 
113. 
114. 
115. 
116. 
117. 
118. 
119. 
Homo sapiens leupaxin mRNA, complete cds {Incyte PD: 
1595756) 
CLEAVAGE SIGNAL-1 PROTEIN {Incyte PD:2054053} 
EST {Incyte PD:1798965} 
Human DNA from overlapping chromosome 19 cosmids R31396, 
F25451, and R31076 containing COX6B and UPKA, genomic 
sequence {Incyte PD:1320685} 
INTERFERON-INDUCED 17 KD PROTEIN {Incyte PD: 
2862971) 
Human homolog of yeast IPP isomerase {Incyte PD:1526240} 
Translation elongation factor 1 gamma {Incyte PD:3138196} 
Tropomyosin alpha chain (skeletal muscle) {Incyte PD:1572555} 
Aplysia ras-related homolog 9 {Incyte PD:2733928} 
ATP SYNTHASE ALPHA CHAIN, MITOCHONDRIAL 
PRECURSOR {Incyte PD:3206210} 
Homo sapiens androgen receptor associated protein 24 
(ARA24) mRNA, complete cds {Incyte PD:552654} 
Glucagon {Incyte PD:1333075} 
Human enhancer of rudimentary homolog mRNA, complete 
cds {Incyte PD:1704472} 
TRANSCRIPTIONAL ENHANCER FACTOR TEF-1 {Incyte 
PD:2957175} 
Ubiquitin-like protein {Incyte PD:1754454} 
Human RGP4 mRNA, complete cds {Incyte PD:617517} 
Cellular retinol-binding protein {Incyte PD:1612969} 
Ornithine decarboxylase 1 {Incyte PD:1930235} 
EST {Incyte PD:3605632} 
EST {Incyte PD:2057260} 
ESTs, Weakly similar to CAMP-DEPENDENT PROTEIN 
KINASE TYPE 2 [Saccharomyces cerevisiae] 
{Incyte PD:2055611} 
Human p37NB mRNA, complete cds {Incyte PD:1407110} 
Human mRNA for suppressor for yeast mutant, complete cds 
{Incyte PD:2888814} 
EST {Incyte PD:3142705} 
ESTs, Weakly similar to K01H12.1 [C.eZegans] {Incyte 
PD:56197} 
Cell division cycle 2, G1 to S and G2 to M {Incyte PD:1525795] 
EST {Incyte PD:1794175} 
EST {Incyte PD:1489557} 
ESTs, Weakly similar to PROTEIN PHOSPHATASE PPZA, 
72 KD REGULATORY SUBUNIT [H. sapiens] 
{Incyte PD:2379045} 
CAMP-DEPENDENT PROTEIN KINASE TYPE 11-ALPHA 
REGULATORY CHAIN {Incyte PD:1649731} 
ESTs, Weakly similar to transcription factor [H.sapiens] {Incyte 
PD:1637517} 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
0 subunit (oligomycin sensitivity conferring protein) 
{Incyte PD:2193246} 
RAS-LIKE PROTEIN TC21 {Incyte PD:2505425} 
Small nuclear ribonucleoprotein polypeptides B and B1 {Incyte 
PD:2071473} 
EST {Incyte PD:1922084} 
Proliferating cell nuclear antigen {Incyte PD:2781405} 
ESTs, Highly similar to HIGH MOBILITY GROUP-LIKE 
NUCLEAR PROTEIN 2 [Saccharomyces cerevisiae] 
{Incyte PD:2669174} 
EST {Incyte PD:1844150} 
Human mRNA for proteasome subunit HsC10-11, complete 
cds {Incyte PD:1737833} 
Homo sapiens mRNA for STlC2, complete cds {Incyte 
PD:3993007} 
Human dual specificity phosphatase tyrosineiserine mRNA, 
complete cds {Incyte PD:1514573} 
Human stimulator of TAR RNA binding (SRB) mRNA, complete 
cds {Incyte PD:2057162} 
EST {Incyte PD:2507206} 
H.sapiens mRNA for Ndr protein kinase {Incyte PD:3318571} 
ESTs, Weakly similar to Grb2-related adaptor protein [H.sapiens] 
{Incyte PD:1857259} 
ESTs, Highly similar to Tbcl [M.muscuZus] {Incyte PD:1889147} 
GTPase-activating protein ras p21 (RASA) {Incyte PD:147344} 
Human mRNA for KIAA0123 gene, partial cds {Incyte 
PD:1752436} 
Synteni: YCFR 22 {YC 22.2OOO.Y} 
5 120. 
121. 
122. 
123. 
10 124. 
125. 
126. 
1s 127. 
128. 
129. 
130. 
2o 131. 
132. 
133. 
134. 
135. 
136. 
25 137. 
138. 
139. 
30 140. 
141. 
142. 
143. 
144. 
145. 
146. 
147. 
4o 148. 
149. 
150. 
151. 
152. 
45 153. 
154. 
155. 
SO 156. 
157. 
158. 
159. 
160. 
5s 161. 
162. 
163. 
164. 
165. 
6o 166. 
167. 
168. 
65 169. 
3 s  
Human non-histone chromosomal protein (NHC) mRNA, 
complete cds {Incyte PD:1748670} 
Thioredoxin {Incyte PD:2606240} 
FATTY ACID-BINDING PROTEIN, EPIDERMAL {Incyte 
PD:2537805} 
Proteasome component C2 {Incyte PD:2195309} 
Homo sapiens heat shock protein hsp40 homolog mRNA, 
complete cds {Incyte PD:2844989} 
Human amyloid precursor protein-binding protein 1 mRNA, 
complete cds {Incyte PD:1663083} 
Homo sapiens DNA binding protein homolog (DRIL 1) 
mRNA, complete cds {Incyte PD:2538333} 
Human Has2 mRNA, complete cds {Incyte PD:3602403} 
EST {Incyte PD:1749678} 
Homo sapiens golgi SNARE (GS27) mRNA, 
complete cds {Incyte PD:3279439} 
ESTs, Weakly similar to UBIQUlTIN-ACTIVHING ENZYME 
E l  HOMOLOG [H.sapiens] {Incyte PD:1710472} 
Synteni: YCFR 22 {YC 22.2000.N) 
Voltage-dependent anion channel 2 {Incyte PD:2189062} 
Human rap2 mRNA for ras-related protein {Incyte PD:3334979] 
Acid phosphatase 1, soluble {Incyte PD:620871} 
Human clone 23840 mRNA, partial cds {Incyte PD:1830083} 
Human mRNA for K I A A O O O 8  gene, complete cds {Incyte 
PD:1970111} 
H.sapiens mRNA for protein-tyrosine-phosphatase 
(tissue type: foreskin) {Incyte PD:444957} 
Human B-cell receptor associated protein (hBAP) mRNA, 
partial cds {Incyte PD:2545562} 
ESTs, Highly similar to ring finger protein [H.sapiens] {Incyte 
PD:2860918) 
H.sapiens mRNA for CLPP {Incyte PD:2675481} 
APOPTOSIS REGULHOR BCL-X {Incyte PD:1855683} 
PROTEASOME COMPONENT C13 PRECURSOR {Incyte 
PD:2668334} 
Sorting nexin 1 {Incyte PD:1508407} 
Human voltage dependent anion channel form 3 mRNA, 
complete cds {Incyte PD:2051154} 
H.sapiens mRNA for translin {Incyte PD:986855} 
Human DEAD-box protein p72 (P72) mRNA, complete 
cds {Incyte PD:1750553} 
Ras homolog gene family, member G (rho G) 
{Incyte PD:1342744} 
EST {Incyte PD:1377794} 
Human FEZ2 mRNA, partial cds {Incyte PD:2623268} 
Human homolog of Drosophila discs large protein, isoform 2 
(hdlg-2) mRNA, complete cds {Incyte PD:2203554} 
ALCOHOL DEHYDROGENASE {Incyte PD:1634342} 
3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
(hydroxymethylglutaricaciduria) {Incyte PD:1695917} 
ENOYL-COA HYDRHASE, MlTOCHONDRIAL PRECURSOR 
{Incyte PD:2235870} 
Proteasome (prosome, macropain) subunit, beta type, 6 {Incyte 
PD:2989852} 
INTERFERON GAMMA UP-REGULATED 1-5111 PROTEIN 
PRECURSOR {Incyte PD:2211625} 
Epimorphin {Incyte PD:3438987} 
H.sapiens RY-1 mRNA for putative nucleic acid binding 
protein {Incyte PD:1805712} 
EST {Incyte PD:1905120} 
KD HOUSEKEEPING PROTEIN {Incyte PD:1819287} 
Cytochrome c oxidase subunit V I h  {Incyte PD:2060789} 
EST {Incyte PD:661516} 
Homo sapiens nuclear VCP-like protein NVLp.2 (NVL.2) mRNA, 
complete cds {Incyte PD:1445507} 
EST {Incyte PD:1251588} 
EST {Incyte PD:1665871} 
Homo sapiens inositol polyphosphate 4-phosphatase type 11-alpha 
mRNA, complete cds {Incyte PD:3032739} 
Homo sapiens arsenite translocating H P a s e  (ASNA1) mRNA, 
complete cds {Incyte PD:1666094} 
Human SnRNP core protein Sm D3 mRNA, complete cds {Incyte 
PD:1624865} 
Homo sapiens clone 23777 putative transmembrane 
GTPase mRNA, partial cds {Incyte PD:2554541} 
Homo sapiens regulator of G protein signaling RGS12 
(RGS) mRNA, complete cds {Incyte PD:3618382} 
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TABLE 6-continued 
Down Regulated Genes in Descending Order (Highest to lowest) 
170. Human Ki nuclear autoantigen mRNA, complete cds {Incyte 5 
PD:1308112} 
Homo sapiens peroxisomal phytanoyl-CoA alpha-hydroxylase 
(PAHX) mRNA, complete cds {Incyte PD:4073867} 
PD:1222317} 
PRECURSOR {Incyte PD:1552335} 
Human clone C4E 1.63 (CAC)n/(GTG)n repeat-containing mRNA 
{Incyte PD:1928789} 
Human glioma pathogenesis-related protein (GliPR) mRNA, 
complete cds {Incyte PD:477045} 
Homeo box A9 {Incyte PD:459651} 
171. 
172. PLACENTAL CALCIUM-BINDING PROTEIN {Incyte 
173. PRE-MRNA SPLICING FACTOR SF2, P32 SUBUNlT 10 
174. 
175. 
176. 15 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
3s. 
36. 
37. 
TABLE 6 
20 
Waveform Up Regulated Genes in Ascending Order (Lowest to Highest) 
NEUROMEDIN B PRECURSOR (Incyte PD:2754315} 
Synteni: YCFR 21 {YC 21.0031.N) 
ATRIAL NATRIURETIC PEPTIDE CLEARANCE RECEPTOR 
PRECURSOR {Incyte PD:1353606} 
Synteni: YCFR 85 {YC 85.2OOO.Y} 
Homo sapiens CHD3 mRNA, complete cds {Incyte PD:1965248} 
EST {Incyte PD:565872} 
Synteni: YCFR 46 Cy3 {YC 46.2000.Z) 
ESTs, Weakly similar to metaxin [H.sapiens] {Incyte PD: 
1754461) 
Plasminogen {Incyte PD2515873) 
Human mRNA for CC chemokine LARC precursor, complete cds 
{Incyte PD:2220923} 
Synteni: YCFR 21 {YC 21.0062.N) 
Homo sapiens Amplified in Breast Cancer (AIB1) mRNA, 
complete cds {Incyte PD:2634478} 
Homo sapiens clone 24640 mRNA sequence {Incyte PD:1560143} 
Synteni: YCFR 21 {YC 21.2000.N} 
EST {Incyte PD:143912} 
Human transcription factor SIM2 long form mRNA, complete cds 
{Incyte PD:996104} 
EST {Incyte PD:2841478} 
PUTATIVE DNA BINDING PROTEIN AZO {Incyte 
PD:1878791} 
Protein tyrosine phosphatase, receptor type, mu polypeptide 
{Incyte PD:987736} 
Human clone A9A2BRBS (CAC)n/(GTG)n repeat-containing 
mRNA {Incyte PD:1987975} 
Endothelin converting enzyme 1 {Incyte PD:1963819} 
BB1 {Incyte PD:1966148} 
Pleiotrophin (heparin binding growth factor 8, neurite 
growth-promoting factor 1) {Incyte PD:2989411} 
Argininosuccinate synthetase {Incyte PD: 1981145) 
Human breast epithelial antigen BA46 mRNA, complete cds 
{Incyte PD:1319020} 
Human clone 46690 brain expressed mRNA from chromosome X 
{Incyte PD:1669780} 
Human plectin (PLEC1) mRNA, complete cds {Incyte 
PD:1907232} 
Homo sapiens mRNA for calmegin, complete cds 
{Incyte PD:2498216} 
EST {Incyte PD:769182} 
Amyloid beta (A4) precursor-like protein 2 {Incyte PD:3876715} 
Polymerase (RNA) I1 (DNA directed) polypeptide A (220kD) 
{Incyte PD:1382059} 
GLUCOSE TRANSPORTER TYPE 3, BRAIN {Incyte 
PD:2745082} 
Homo sapiens sarco-/endoplasmic reticulum Ca-ATPase 3 
(ATP2A3) mRNA, alternatively spliced, partial cds 
{Incyte PD:688411} 
Human c-jun proto oncogene (JUN), complete cds, clone 
h U - 1  {Incyte PD:1969563} 
Microtubule-associated protein 1A {Incyte PD:702684} 
Clusterin (complement lysis inhibitor; testosterone-repressed 
prostate message 2; apolipoprotein J) {Incyte PD:2966620} 
NADH-CYTOCHROME BS REDUCTASE {Incyte PD:1901142} 
Waveform Up Regulated Genes in Ascending Order (Lowest to Highest) 
38. Protein-tyrosine kinase 7 {Incyte PD:996229} 
39. Alpha-1 type XVI collagen {Incyte PD:1963529} 
40. EST {Incyte PD:2839121} 
41. Homo sapiens mRNA for DEC1, complete cds 
{Incyte PD:1732479} 
42. Human endogenous retroviral protease mRNA, complete 
cds {Incyte PD:1347636} 
43. ATPase, Na+/K+ transporting, alpha 1 polypeptide 
{Incyte PD:1730609} 
44. Laminin, alpha 4 {Incyte PD:1851696} 
45. Hexabrachion (tenascin C, cytotactin) {Incyte PD:1453450} 
46. Human mRNA for KIAA0325 gene, partial cds 
{Incyte PD:1995315} 
47. Integrin beta-5 subunit {Incyte PD:418731} 
48. Microfibrillar-associated protein 4 {Incyte PD:1659231} 
49. Fibulin 1 {Incyte PD:1320658} 
SO. Protein serineithreonine kinase stk2 {Incyte PD:1518981} 
51. ESTs, Weakly similar to HYPOTHETICAL 16.1 KD PROTEIN 
IN SEC 17-QCR1 INTERGENIC REGION 
[Saccharomyces cerevisiae] {Incyte PD: 1923722) 
Homo sapiens carbonic anhydrase precursor (CA 12) mRNA, 
complete cds (Incyte PD:3766382} 
52. 
53. 
54. 
55. 
25 56. 
57. 
58. 
59. 
30 60. 
61. 
62. 
63. 
64. 
65. 
66. 
67. 
40 68. 
69. 
70. 
71. 
45 72. 
73. 
74. 
7s. 
SO 76. 
77. 
78. 
79. 
80. 
81. 
82. 
60 83’ 
84. 
85. 
86. 
65 87. 
88. 
3 s  
55 
H.sapiens mRNA for SIX1 protein {Incyte PD:3208486} 
Plasminogen activator inhibitor, type I {Incyte PD:1445767} 
Human mRNA for SHPS-1, complete cds {Incyte PD:2180684} 
Collagen, type V, alpha 1 {Incyte PD:1672442} 
Homo sapiens monocarboxylate transporter (MCT3) mRNA, 
complete cds {Incyte PD:1343253} 
Human follistatin gene {Incyte PD:1577614} 
Human putative RNA binding protein (RBP56) mRNA, complete 
cds {Incyte PD:1907369} 
Homo sapiens mRNA for PRP8 protein, complete cds 
{Incyte PD:3616229} 
Homo sapiens CAGH3 mRNA, complete cds {Incyte PD: 
1432042) 
EST {Incyte PD:2953888} 
Intercellular adhesion molecule 1 (CD54), human 
rhinovirus receptor {Incyte PD:1556061} 
Human p120E4F transcription factor mRNA, complete cds 
{Incyte PD:1940164} 
Collagen, type VI, alpha 1 {Incyte PD:2672056} 
Human mRNA for pM5 protein {Incyte PD:1578951} 
ALZHEIMER’S DISEASE AMYLOID A4 PROTEIN 
PRECURSOR {Incyte PD:126370} 
Human mRNA for KIAA0062 gene, partial cds 
{Incyte PD:3138128} 
Human clone HSHl HMG CoA synthase mRNA, partial 
cds {Incyte PD:1807407} 
Filamin 1 (actin-binding protein-280) {Incyte PD:1708528} 
Synteni: YCFR 85 {YC 85.2OOO.X} 
Synteni: YCFR 46 Cy3 {YC 46.2000.W) 
Homologue of mouse tumor rejection antigen gp96 {Incyte 
PD:2679349} 
Tissue inhibitor of metalloproteinase 3 (Sorsby fundus 
dystrophy, pseudoinflammatory) {Incyte PD:418041} 
Human XMP mRNA, complete cds {Incyte PD:1887661} 
Cytochrome P450, subfamily XIA (cholesterol side chain 
cleavage) {Incyte PD:2368282} 
Granulin {Incyte PD:812141} 
Human extracellular matrix protein 1 (ECM1) mRNA, complete 
cds {Incyte PD:1965806} 
78 KD GLUCOSE REGULHED PROTEIN PRECURSOR 
{Incyte PD:2884613} 
Synteni: YCFR 21 {YC 21.2OOO.X} 
Homo sapiens mRNA for serin protease with IGF-binding 
motif, complete cds {Incyte PD:1958902} 
Inhibitor of DNA binding 1, dominant negative helix-loop- 
helix protein {Incyte PD:1687060} 
Solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 {Incyte PD:1516886} 
Hormone receptor (growth factor-inducible nuclear protein 
N10) {Incyte PD:1958560} 
Fibulin 2 {Incyte PD:1901095} 
Kinase insert domain receptor (a type 111 receptor tyrosine 
kinase) {Incyte PD:2220338} 
Synteni: YCFR 45 {YC 45.2000.X} 
Syndecan 4 (amphiglycan, ryudocan) {Incyte PD:3214670} 
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TABLE 6-continued 
Waveform Up Regulated Genes in Ascending Order (Lowest to Highest) 
89. 
90. 
91. 
92. 
93. 
94. 
9s. 
96. 
97. 
98. 
99. 
100. 
101. 
102. 
103. 
104. 
105. 
106. 
107. 
108. 
109. 
110. 
111. 
112. 
113. 
114. 
115. 
116. 
117. 
118. 
119. 
120. 
121. 
122. 
123. 
124. 
125. 
126. 
127. 
128. 
129. 
130. 
131. 
132. 
133. 
134. 
135. 
136. 
137. 
138. 
139. 
140. 
Synteni: YCFR 21 {YC 21.0500.N) 
Human pre-B cell enhancing factor (PBEF) mRNA, complete 
cds {Incyte PD:1641590} 
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) 
{Incyte PD:168865} 
Latent transforming growth factor beta binding protein 1 
{Incyte PD:1313183} 
Lysyl hydroxylase {Incyte PD:1759127} 
Human mRNA for KIAA0230 gene, partial cds {Incyte PD: 
1449824) 
Human mRNA for dihydropyrimidinase related protein-2, 
complete cds {Incyte PD:2784546} 
H.sapiens garp gene mRNA, complete CDS {Incyte 
PD:3572014} 
EST {Incyte PD:724880} 
ESTs, Weakly similar to TRANSMEMBRANE PROTEIN SEX 
PRECURSOR [H.sapiens] {Incyte PD:1511346} 
Human contactin associated protein (Caspr) mRNA, 
complete cds {Incyte PD:2309047} 
Human cysteine-rich fibroblast growth factor receptor 
(CFR-1) mRNA, complete cds {Incyte PD:2204871} 
EST {Incyte PD:2580841} 
Collagen, type V, alpha {Incyte PD:1887959} 
H.sapiens RNA for type VI collagen alpha3 chain {Incyte 
PD:1314882} 
Protein kinase C substrate 80K-H {Incyte PD:1723971} 
Fibrillin 1 (Marfan syndrome) {Incyte PD:1448051} 
Collagen, type XI, alpha 1 {Incyte PD:3598222} 
H.sapiens mRNA for extracellular matrix protein 
collagen type XIV, C-terminus {Incyte PD:2208990} 
Collagen, type 11, alpha 1 (primary osteoarthritis, 
spondyloepiphyseal dysplasia, congenital) 
{Incyte PD:2518178} 
ESTs, Weakly similar to unknown [S.cerevisiae] 
{Incyte PD:2171401} 
EST {Incyte PD:1923572} 
Human insulin-like growth factor binding protein 5 
(IGFBPS) mRNA {Incyte PD:1686585} 
Human mRNA for KIAA0242 gene, partial cds 
{Incyte PD:1940994} 
Complement component 1, s subcomponent {Incyte PD:1904751} 
Human chromosome 17 unknown product mRNA, complete cds 
{Incyte PD:2849603} 
Homo sapiens lysosomal pepstatin insensitive protease 
(CLN2) mRNA, complete cds {Incyte PD:3500996} 
Collagen, type IV, alpha 2 {Incyte PD:1906574} 
ESTs, Moderately similar to ZINC FINGER PROTEIN HE12 
[Homo sapiens] {Incyte PD:3729155} 
Homo sapiens stanniocalcin precursor (STC) mRNA, complete 
cds {Incyte PD:2222921} 
P55-C-FOS PROTO-ONCOGENE PROTEIN {Incyte PD:341491] 
EST {Incyte PD:2424631} 
EST {Incyte PD:1940710} 
Thrombospondin 1 {Incyte PD:2055534} 
Complement component Cl r  {Incyte PD:1664320} 
REGULATOR OF G-PROTEIN SIGNALLING 2 {Incyte PD: 
1218114) 
INTEGRAL MEMBRANE PROTEIN E16 {Incyte PD:1911012} 
Collagen, type I, alpha 1 {Incyte PD:782235} 
H.sapiens mRNA for adipophilin {Incyte PD:1985104} 
EST {Incyte PD:1979450} 
EST {Incyte PD:690994} 
Cathepsin D (lysosomal aspartyl protease) {Incyte PD:3940755} 
Matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 
72kD type IV collagenase) {Incyte PD:1558081} 
Cyclin D2 {Incyte PD:1618422} 
EST {Incyte PD:2636514} 
COMPLEMENT C3 PRECURSOR {Incyte PD:1513989} 
Homo sapiens secreted frizzled related protein mRNA, 
complete cds {Incyte PD:428236} 
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 
3 PRECURSOR {Incyte PD:1447903} 
Fibronectin 1 {Incyte PD:3553729} 
Early growth response protein 1 {Incyte PD:1705208} 
Human autoantigen DFS70 mRNA, partial cds {Incyte PD:42920} 
Prostaglandin-endoperoxide synthase 2 (prostaglandin 
GIH synthase and cyclooxygenase) {Incyte PD:3139163} 
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Waveform Up Regulated Genes in Ascending Order (Lowest to Highest) 
141. 
142. 
143. 
144. 
145. 
146. 
147. 
148. CARTILAGE GLYCOPROTEIN-39 PRECURSOR {Incyte 
149. 
150. 
151. 
152. 
Synteni: YCFR 43 {YC 43.2000.W) 
Synteni: YCFR 43 {YC 43.2000.Z) 
Synteni: YCFR 23 {YC 23.0062.N) 
Synteni: YCFR 43 {YC 43.2000.Y) 
Homo sapiens phosphomevalonate kinase mRNA, complete 
cds {Incyte PD:1497123} 
Synteni: YCFR 43 {YC 43.2000.X) 
Synteni: YCFR 23 {YC 23.0031.N) 
PD:157510} 
Synteni: YCFR 23 {YC 23.0125.N) 
Synteni: YCFR 23 {YC 23.0250.N) 
Synteni: YCFR 23 {YC 23.4000.N) 
Human germline oligomeric matrix protein (COMP) mRNA, 
complete cds {Incyte PD:2636634} 
EXAMPLE 7 
Prototype of the System 
FIGS. 10 and 11 are partially diagrammatic representa- 
tions of one embodiment of the system 1. Spherical disks 2 
of biocompatable material are arranged along the horizontal 
spin filter or horizontal oxygenator of a standard rotating 
wall perfused vessel or rotating wail batch-fed vessel 5 .  
The electrically conductive, bioattractive strips 6 are each 
suitably embedded in or affixed to each of the disks such that 
each disk has a positive and negative pole 12, associated 
with positive and negative terminals 12 connected to respec- 
tive endportions of the strips, as shown in FIG. 11A. As will 
be more fully described, in one preferred embodiment in 
which an alternating current is applied to the strips, the 
polarity of the strips changes cyclically in correspondence 
with the change in polarity of the applied current. Each 
biocompatable disk is preferably two-sided, allowing 
growth of tissue on both the left and right portions of the 
spherical disk. Sterilization of the reactor core is effected by 
one of multiple sterilization procedure, either ethylene oxide 
sterilization, autoclave sterilization if the polymer permits, 
or in the case of the batch-fed vessel, sterilization with 
hydrogen peroxide. After sterilization and sufficient detoxi- 
fication procedures, cellular material is seeded into the 
reactor at a level to be determined according to the cell line 
of interest. 
A source of time varying current 10, suitably a laboratory 
current source with adjustable wave-form output connected 
to a remote power source, not shown, is operable to provide 
a time varying current, suitably of a value of about 1 mA to 
about 1,000 mA, in the present embodiment. The time 
varying current is suitably an alternating current, as indi- 
cated above, although in other embodiments it is a pulsating 
DC current. The current is conducted from the source 10 
along first and second conductors 13A and 13B to slip rings 
4. The slip rings are non-rotatable relative to the vessel 5,  
and therefore rotate with the vessel during operation. Cur- 
rent received through conductors 13A and 13B is conducted 
through the associated slip rings to first and second sets of 
conductors, represented by first and second conductors 14A 
and 14B, which are preferably insulated with an insulative 
material, not shown, compatible with the fluids and products 
within the bioreactor chamber. Each conductor is mechani- 
cally connected to a respective peripheral portion of each of 
the respective discs, and electrically connected with an end 
portion of one of the conductive strips 6 (FIGS. 11A and 
11B). As viewed in FIG. 10, conductor 14A and the asso- 
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ciated slip ring are indicated to be of positive (+) polarity, 
and conductor 14B and its associated slip ring are indicated 
to be of relatively negative (-) polarity. As suggested above, 
upon the current changing in polarity, conductor 14A will 
momentarily have a negative potential relative to conductor 
14B, thereby permitting a time varying current, which in this 
embodiment is an alternating current, to flow through con- 
ductor 6 which. In other embodiments, the time-varying 
current may be in the form of a pulsating DC current, 
suitably a square wave or other waveform, rather than an 
alternating current, in which case the conductors 14A and 
14B and their associated slip rings remain of the same 
polarity but of differing potentials. 
After inoculation, the rotating wall vessel 5 is rotated at 
an appropriate speed and single cellular material begins to 
attach onto the surface of the biocompatable material 6. 
After initial growth of one 24- or 48-hour period, electrical 
stimulation, i.e., potentiation, begins via continuous low- 
level or pulsatile electrical flow through each disk in series. 
Discussion 
Use of the methods of the present invention to control the 
proliferative rate of normal human adult astrocytes and 
normal human neural progenitor cells (NHNP) has been 
demonstrated. The procedure is applicable to, but not limited 
to, the control of normal human neural cells in both two- 
dimensional and three-dimensional culture. As presented in 
the molecular genetic data shown in Table 5 and Table 6, 
many of the genetic responses in both up regulated and down 
regulated genes are maturation and growth regulatory in 
nature. An inspection reveals these genes are also primarily 
involved in the embryogenic process. Therefore it is rea- 
sonable to conclude that control over the embryogenic 
development process can be achieved via the presently 
demonstrated methodology. 
As shown in Table 6, specific genes such as human 
germline oligomeric matrix protein, prostaglandin endoper- 
oxide synthase 2, early growth response protein 1, and 
insulin like growth factor binding protein 3 precursor are 
highly up regulated, while Keratin Type I1 cytoskelatal 7, 
mytotic kinesin like protein 1, transcription factor 6 like 1, 
mytotic feedback control protein, and cellular retinoic acid 
binding protein are down regulated (Table 5). Each of these 
two sets or classes of genes are only examples from the sum 
of approximately 320 genes changes expressed as a conse- 
quence of exposure to electrical potentiation. 
As is clearly demonstrated in the human body, the 
bioelectric, biochemical process of electrical nerve stimula- 
tion is a documented reality. The present invention demon- 
strates that the same phenomena can be potentiated in a 
synthetic atmosphere, i.e., in rotating wall cell culture ves- 
sels. As may be understood from the forgoing discussion, 
this electrical potentiation can be used for a number of 
purposes. 
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Any patents or publications mentioned in this specifica- 
tion are indicative of the levels of those skilled in the art to 
which the invention pertains. These patents and publications 
are herein incorporated by reference to the same extent as if 
5 each individual publication was specifically and individually 
indicated to be incorporated by reference. 
One skilled in the art will readily appreciate that the 
present invention is well adapted to carry out the objects and 
obtain the ends and advantages mentioned, as well as those 
inherent therein. The present examples along with the 
methods, procedures, treatments, molecules, and specific 
compounds described herein are presently representative of 
preferred embodiments, are exemplary, and are not intended 
as limitations on the scope of the invention. Changes therein 
and other uses will occur to those skilled in the art which are 
encompassed within the spirit of the invention as defined by 
the scope of the claims. 
What is claimed is: 
1. A system for growing biological cells, comprising: 
a rotating cell culture vessel; 
a cell culture medium contained within said rotating cell 
culture vessel; 
an electrode; and 
an electrical circuit connected to said electrode for pass- 
ing a time varying electrical current through said elec- 
trode for generating a time varying electromagnetic 
field within said cell culture medium. 
2. The system of claim 1, wherein said time varying 
3. The system of claim 1, wherein said time varying 
4. The system of claim 1, wherein said electrode is 
adjacent to and spaced from said rotational cell culture 
vessel. 
5 .  The system of claim 1, wherein said electrode is 
6. The system of claim 1, wherein said electrical current 
is from about 1 mA to about 1,000 mA. 
7. The system of claim 6, wherein said time varying 
electrical current is about 1 milliamperes to about 6 milli- 
8. The system of claim 1, wherein said time varying 
electromagnetic field induces a cellular response at gene 
level. 
9. The system of claim 8, wherein said cellular response 
45 is cellular control of growth and differentiation at gene level. 
10. The system of claim 9, wherein said cellular control 
of growth and differentiation is to suppress or enhance 
growth regulatory functions at gene level. 
11. The system of claim 10, wherein said gene is associ- 
12. The system of claim 1, wherein said electrode is made 
of a material selected from the group consisting of titanium, 
zirconium, platinum and stainless steel. 
13. The system of claim 1, wherein said electrode com- 
ss prises an antenna for emitting said time varying electromag- 
netic field within said cell culture medium. 
14. The system of claim 13, wherein said antenna is 
positioned adjacent said rotating cell culture vessel, said 
antenna comprising means for inducing an electromagnetic 
60 field within said medium within said rotating cell culture 
vessel. 
15. The system for growing biological cells of claim 1, 
wherein the frequency of said time varying electrical current 
is approximately 10 Herz. 
16. A system for growing biological cells in a two- 
dimensional array, wherein said cells exhibit accelerated 
growth, comprising: 
10 
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electrical current is in the form of an alternating current. 
30 electrical current is in the form of a square wave. 
35 positioned within said rotational cell culture vessel. 
40 amperes. 
SO ated with embryogenesis. 
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a cell culture medium; 
a container; 
an electrode positioned within said container; 
said biological cells, wherein said biological cells con- 
tained in said cell culture medium are bubbled onto said 
electrode; and 
an electrical circuit connected to said electrode for pass- 
ing a time varying electrical current through said elec- 
trode for generating a time varying electromagnetic 
field within said cell culture medium. 
17. The system of claim 16, wherein said electrode is 
18. The system of claim 16, wherein said electrode is 
19. The system of claim 16, wherein said biological cells 
20. The system of claim 16, further comprising: 
a slide placed on said electrode wherein said biological 
cells contained in said cell culture medium are bubbled 
thereon. 
21, The system of claim 16, wherein said time varying 
electrical current is in the form of an alternating current, 
22. The system of claim 16, wherein said time varying 
electrical current is in the form of a square wave. 
23. The system of claim 16, wherein said electrical current 
is from about 1 millamperes to about 1,000 1 millamperes. 
24. The system of claim 16, wherein said electrical current 
is from about 1 millamperes to about 6 millamperes. 
25. The system of claim 16, wherein said electrical is 
made of a material selected from the group consisting of 
positioned adjacent said container. 
positioned within said container. 1~ titanium, zirconium, platinum and stainless steel. 
comprise neural cells. * * * * *  
